Genetic disorders of motor neurons

Seminars in Neurology

Volumn 19, Issue 4, 1999, Pages 407-418

  Cole, N ^a   Siddique, T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Amyotrophic lateral sclerosis; Genes; Genetics; Kennedy disease; Motor neuron disorders; Neurodegeneration; Spinal muscular atrophy

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CASPASE INHIBITOR; CHELATING AGENT; COPPER; CREATINE; GABAPENTIN; GENISTEIN; GLUTATHIONE PEROXIDASE; RILUZOLE; TRIENTINE;

AMYOTROPHIC LATERAL SCLEROSIS; CHROMOSOME MAP; DEGENERATIVE DISEASE; DEMENTIA; DISABILITY; GENE MUTATION; GENETIC LINKAGE; HUMAN; KENNEDY DISEASE; MOLECULAR CLONING; MOTOR NEURON DISEASE; MOUSE; NEUROFILAMENT; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPASTIC PARAPLEGIA; SPINAL MUSCULAR ATROPHY;

EID: 0033381436     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1040855     Document Type: Review

References (123)

1. Dubowitz V. Muscle disorders in childhood. 2nd ed. London: W.B. Saunders; 1995
2. Emery AEH. The nosology of the spinal muscular atrophies. J Med Genet 1971;8:481-495
3. Crawford TO, Pardo CA. The neurobiology of childhood spinal muscular atrophy. Neurobiol Dis 1996;3:97-110
4. Brzustowicz LM, Lehner T, Castilla LH, et al. Genetic mapping of chronic childhood onset spinal muscular atrophy to chromosome 5q11.2-13.3. Nature 1990;345:823-825
5. Matthijs G, Schollen E, Legius E, Devriendt K, Goemans N, Kayserili H, et al. Unusual molecular findings in autosomal recessive spinal muscular atrophy. J Med Genet 1996;33:469-474
6. Burglen L, Lefebvre S, Clement O, et al. Structure and organization of the human survival motor neurone (SMN) gene. Genomics 1996;32:479-482
7. Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995;80:155-165
8. Lefebvre S, Burglen L, Frezal J, Munnich A, Melki J. The role of the SMN gene in proximal spinal muscular atrophy. Hum Mol Genet 1998;7:1531-1536
9. Lefebvre S, Burlet P, Liu Q, et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nature Genet 1997;16:265-269
10. Talbot K, Miguel-Ahaga I, Mohaghegh P, Ponting CP, Davies KE. Characterization of a gene encoding survival motor neurons (SMN)-related protein, a constituent of the spliceosome complex. Hum Mol Genet 1998;7:2149-2156
11. Biros I, Forrest S. Spinal muscular atrophy: Untangling the knot? J Med Genet 1999;36(1):1-8
12. Talbot K. Spinal muscular atrophy. J Inherit Metab Dis 1999;22 (4):545-554
13. Liu Q, Dreyfuss G. A novel nuclear structure containing the survival of motor neurons protein. EMBO J 1996; 15:3555-3565
14. Murayama S, Bouldin TW, Suzuki K. Immunological and ultrastructural studies of Werdnig-Hoffmann disease. Acta Neuropathol 1991;81:408-417
15. Liu Q, Fisher U, Wang F, Dreyfuss G. The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal sn RNP proteins. Cell 1997;90:1013-1021
16. Fisher U, Liu Q, Dreyfuss G. The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis. Cell 1997;90: 1023-1029
17. Pellizzoni I, Kataoka N, Charroux B, Dreyfuss G. A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing. Cell 1998;95:615-624
18. Strasswimmer J, Lorson CL, Breiding DE, Chen JJ, Le T, Burghes AH, Androphy EJ. Identification of survival motor neuron as a transcriptional activator-binding protein. Hum Mol Genet 1999;8(7):1219-1226
19. Iwahashi H, Eguchi Y, Yasuhara N, Hanafusa T, Matsuzawa Y, Tsujimoto Y. Synergistic anti-apopotic activity between Bcl-2 and SMN implicated in spinal muscular atrophy. Nature 1997;390:413-417
20. Van der Steege G, Grootscholten PM, van der Vlies P, et al. PCR-based DNA test to confirm clinical diagnosis of autosomal recessive spinal muscular atrophy. Lancet 1995;345:985-986
21. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 1999; 96(11):6307-6311
22. Monani UR, Losen CL, Parsons DW, Prior TW, Androphy EJ, Burghes AH, McPherson JD. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet 1999;8(7): 1177-1183
23. Gennarelli M, Lucarelli M, Capon F, et al. Survival motor neuron gene transcript analysis in muscles from spinal muscular atrophy patients. Biochem Biophys Res Commun 1995;213:342-348
24. Taylor JE, Thomas NH, Lewis CM, et al. Correlation of SMN1 and SMNc gene copy number with age of onset and survival in spinal muscular atrophy. Eur J Hum Genet 1998;6:467-474
25. Campbell L, Potter A, Ignatius J, Dibowitz V, Davies K. Genome variation and gene conversion in spinal muscular atrophy: Implications for disease process and clinical phenotype. Am J Hum Genet 1997;61:40-50
26. Velasco E, Valero C, Valero A, Moreno F, Hernandez-Chico C. Molecular analysis of the SMN and NAIP genes in Spanish spinal muscular atrophy (SMA) families and correlation between number of copies of cBCD541 and SMA phenotype. Hum Mol Genet 1996;5:257-263
27. Gendron NH, Mc Kenzie AE. Spinal muscular atrophy: Molecular pathophysiology. Curr Opinion Neurol 1999; 12:137-142
28. Roy N, Mahadevan MS, Mc Lean M, et al. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 1995;80:167-178
29. 29. Parboosingh JS, Meininger V, McKenna-Yasek D, Brown RH Jr, Rouleau GA. Deletions causing spinal muscular atrophy do not predispose to amyotrophic lateral sclerosis. Arch Neurol 1999;56(6):710-712
30. 30. Scharf JM, Endrizzi MG, Wetter A, et al. Identification of a candidate modifying gene for spinal muscular atrophy by comparative genomics. Nat Genet 1998;20(1):83-86
31. Eng GD, Binder H, Koch B. Spinal muscular atrophy: Experience in diagnosis and rehabilitation of 60 patients. Arch Phys Med Rehabil 1984;65:549-553
32. Fischbeck KH. Kennedy disease. J Inherit Metab Dis 1997;20: 152-158
33. Nance MA. Clinical aspects of CAG repeat diseases. Brain Pathol 1997;3:881-900
34. Perutz MF. Glutamine repeats and inherited neurodegenerative diseases: Molecular aspects. Curr Opin Struct Biol 1996;6: 848-858
35. Ross CA. When more is less: Pathogenesis of glutamine repeat neurodegenerative diseases. Neuron 1995;15:493-496
36. Markus W, Eisen A. Assessment of upper and lower motor neurons in Kennedy's disease: Implications for corticomotoneuronal PSTH studies. Muscle and Nerve 1999;22:299-306
37. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fishbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991;352:77-79
38. 38. Li M, Miwa S, Kobayashi Y, et al. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann Neurol 1998;44(2):249-254
39. 39. Kobayashi Y, Li M, Sobue G. In vitro aggregation and cellular toxicity of mutant androgen receptor protein in spinal and bulbar muscular atrophy. Nippon Rinsho 1999;57(4):874-879
40. Wieacker PF, Knoke I, Jakubiczka S. Clinical and molecular aspects of androgen receptor defects. Exp Clin Endocrinol Diabetes 1998;106:446-453
41. 41. Ellerby LM, Hackam AS, Propp SS, et al. Kennedy's disease: Caspase cleavage of the androgen receptor is a crucial event in cytotoxicity. J Neurochem 1999;72(1):185-195
42. 42. Hsiao P-W, Lin DL, Nakao R, Chang C. The linkage of Kennedy's disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator. J Biol Chem 1999;274(29):20229-20234
43. Tandan R, Bradley WG. Amyotrophic lateral sclerosis: Part I. Clinical features, pathology, and ethical issues in management. Ann Neurol 1985;18:271-280
44. Kurland LT, Choi NW, Sayre GP. Implication of incidence and geographical patterns on the classification of amyotrophic lateral sclerosis. In: Norris FH, Kurland LT, eds. Motor Neuron Disease: Research on Amyotrophic Lateral Sclerosis and Related Disorders. New York: Grune and Stratton, 1969: 28-50
45. Gubbay SS, Kahana E, Zilber N, et al. Amyotrophic lateral sclerosis: A study of its presentation and prognosis. J Neurol 1985;232:295-300
46. Norris FH. Adult spinal motor neuron disease. In: Vinen PJ, Bruyn GW, eds. Handbook of Clinical Neurology. New York: American Elsevier, 1975:1-56
47. Jacobs L, Bozian D, Heffner RR Jr, et al. An eye movement disorder in amyotrophic lateral sclerosis. Neurology 1981;31: 1282-1287
48. Hirano A, Donnenfeld H, Sasaki S, et al. Fine structural observations of neurofilamentous changes in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 1984;43:461-470
49. Hirano A. Cytopathology of amyotrophic lateral sclerosis. Adv Neurol 1991;56:91-101
50. Rowland LP. Natural history and clinical features of amyotrophic lateral sclerosis and related motor neuron diseases. In: Calin DB, ed. Neurodegenerative Diseases. Philadelphia: WB Saunders, 1994;507-521
51. Kato T, Katagiri T, Hirano A, Kawanami T, Sasaki H. Lewy body-like hyaline inclusions in sporadic motor neuron disease are ubiquinated. Acta Neuropathol 1989;77:391-396
52. Mannen T, Iwata M, Toyokura Y, et al. Preservation of a certain motoneurone group of the sacral cord in amyotrophic lateral sclerosis: Its clinical significance. J Neurol Neurosurg Psychiatry 1977;40:464-469
53. Emery AEH, Holloway S. Familial motor neuron disease. In: Howland LP, ed. Human Motor Neuron Disease. New York: Raven Press, 1982;139:147
54. Siddique T, Pericak-Vance MA, Brooks BR. Linkage analysis in familial amyotrophic lateral sclerosis. Neurology 1989;39:919-925
55. Siddique T. Molecular genetics of familial amyotrophic lateral sclerosis. Adv Neurol 1991;56:227-231
56. Hong S, Brooks BR, Hung WY, et al. X-linked dominant locus for late-onset familial amyotrophic lateral sclerosis. Soc Neurosci Abst 1998;24:478
57. Ben Hamida M, Hentati F, Ben Hamida C. Heriditary motor system diseases (chronic juvenile amyotrophic lateral sclerosis): Conditions combining a bilateral pyramidal syndrome with limb and bulbar amyotrophy. Brain 1990;113:347-363
58. Rosen DR, Siddique T, Patterson D, et al. Mutations in CuZn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis [published erratum appears in Nature 1993;364(6435):362] Nature 1993;362:59-62
59. Deng HX, Hentati A, Tainer JA, et al. Amyotrophic lateral sclerosis and structural defects in CuZn superoxide dismutase. Science 1993;261:1047-1051
60. Brown RH Jr. Amyotrophic lateral sclerosis: Insights from genetics. Arch Neurol 1997;54:1246-1250
61. Pardo Ca, Xu Z, Borchelt DR, et al. Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. Proc Natl Acad Sci 1995;89:6109-6113
62. Getzoff ED, Tainer JA, Stempien MM, et al. Evolution of CuZn superoxide dismutase and the Greek key β-Barrel structural motif. Proteins Struct Funct Genet 1989;5:322-336
63. Groner Y, Gieman-Hurwitz J, Dafri N, et al. The human CuZn superoxide dismutase gene family: Architecture and expression of the chromosome 21-encoded functional gene and its processed pseudogenes. In: Rotilis G, ed. Superoxide and Superoxide Dismutase in Chemistry, Biology and Medicine. Amsterdam: Elesiever, 1986
64. Parboosingh JS, Rouleau GA, Meninger V, et al. Absence of mutations in Mn superoxide dismutase or catalase genes in familial amyotrophic lateral sclerosis. Neuromusc Disord 1995;5: 7-10
65. Juneja T, Pericak-Vance M, Laing NG, et al. Prognosis in familial ALS: Progression and survival in patients with E100G and A4V mutations in CuZn superoxide dismutase. Neurology 1997;48:55-57
66. Aoki M, Ogasawara M, Matsubara Y, et al. Familial amyotrophic lateral sclerosis (ALS) in Japan associated with H46R mutation in CuZn superoxide dismutase gene: A possible new subtype of familial ALS. J Neurol Sci 1994;126:77-83
67. Hentati A, Ouahchi K, Pericak-Vance MA, et al. Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers. Neurogenetics 1998;2(1): 55-60
68. Hentati A, Bejaoui K, Pericak-Vance MA, et al. Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33-q35. Nat Genet 1994;7:425-428
69. Hosler BA, Sapp PC, Berger R, et al. Refined mapping and characterization of the recessive familial amyotrophic lateral sclerosis locus (ALS2) on chromosome 2q33. Neurogenetics 1998;2(1):34-42
70. Chance PF, Rabin BA, Ryan SG, et al. Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. Am J Hum Genet 1998;62(3): 633-640
71. Figlewicz DA, Krizus K, Martinoli MG. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet 1994;3: 1757-1761
72. Comi GP, Bordoni A, Salani S, et al. Cytochrome c oxidase subunit1 microdeletion in a patient with motor neuron disease. Ann Neurol 1998;43:110-116
73. Hayward C, Colville S, Swingler RJ, Brook DJH. Molecular genetic analysis of the APEX nuclease gene in amyotrophic lateral sclerosis. Neurology 1999;52:1899-1901
74. Figlewicz DA, Rouleau GA, Krizus A, Julien JP. Polymorphism in the multi-phosphorylation domain of the human neurofilament heavy-subunit-encoding gene. Gene 1993; 132:297-300
75. Al-Chalabi A, Andersen PM, Nilsson P, et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet 1999;8(2):157-164
76. Vechio JD, Bruijn LI, Zuoshang X, Brown RH, Cleveland DW. Sequence variants in human neurofilament proteins: Absence of linkage to familial amyotrophic lateral sclerosis. Ann Neurol 1996;40:603-610
77. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human CuZn superoxide dismutase mutation. Science 1994;264:1772-1775
78. Aguzzi A, Brander S, Sure U, Ruedi D, Isenmann S. Transgenic and knock-out mice: Models of neurological disease. Brain Pathol 1994;4(1):3-20
79. Wong PC, Borchelt DR, Lee MK, et al. Familial amyotrophic lateral sclerosis and Alzheimer's disease. Transgenic models. Adv Exp Med Biol 1998;446:145-159
80. Cole N, Lozar A, Kim M, Siddique T. Age-dependent increase in SOD1 in the spinal cord of ALS-transgenic mice. Soc Neuroscience Abst 1998;486
81. Harris ZL, Gitlin JD. Genetic and molecular basis for copper toxicity. Am J Clin Nutr 1996;63:836S-841S
82. Valentine JS, Gralla EB. Delivering copper inside yeast and human cells. Science 1997;278:817-818
83. Culotta VC, Klomp LWJ, Strain J, Casareno RLB, Krems B, Gitlin GD. The coppei chaperone for superoxide dismutase. J Biol Chem 1997;272:23469-23472
84. Rothstein JD, Dykes-Hoberg M, Corson LB, et al. The copper chaperone CCS is abundant in neurons and astrocytes in human and rodent brain. J Neurochem 1999;72(1):422-429
85. Casereno RLB, Waggoner D, Gitlin JD. The copper chaperone CCS directly interacts with copper/zinc superoxide dismutase. J Biol Chem 1998;273:23625-23628
86. Eum WS, Kang JH. Release of copper ions from the familial amyotrophic lateral sclerosis-associated CuZn-superoxide dismutase mutants. Mol Cells 1999;9(1):110-114
87. Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-158
88. Hugon J, Vallat JM, Dumas M. Role of glutamate and excitotoxicity in neurologic disease. Rev Neurol (Paris) 1996;152: 239-248
89. Doble A. The role of excitotoxicity in neurodegenerative disease: Implications for therapy. Pharmacol Ther 1999;81(3):163-221
90. Shaw CE, Ince PG, Glutamate, excitotoxicity and amyotrophic lateral sclerosis. J Neurol 1997;244(suppl.):S3-14
91. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kunci RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84
92. Trotti D, Rolfs A, Danbolt NC, Brown RH, Hediger MA. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nature Neuroscience 1999;2(5):427-433
93. Lin CL, Bristol LA, Jin L, et al. Aberrant RNA processing in neurodegenerative disease: The cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998;20:589-602
94. Bai G, Lipton SA. Aberrant RNA splicing in sporadic amyotrophic lateral sclerosis. Neuron 1998;20:363-366
95. Nagai M, Abe K, Okamoto K, Itoyama Y. Identification of alternative splicing forms of GLT-1 mRNA in the spinal cord of amyotrophic lateral sclerosis patients. Neurosci Lett 1998;244 (3):165-168
96. Friede RL, Samorajski T. Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice. Anat Rec 1970;167:379-387
97. Hoffman PN, Cleveland DW, Griffin JW, et al. Neurofilament gene expression: A major determinant of axonal caliber. Proc Natl Acad Sci USA 1937;84:3472-3476
98. Xu Z, Cork LC, Griffin JW, Cleveland DW. Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease. Cell 1993;73:23-33
99. Core F, Collard JF, Julien JP. Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: A mouse model of amyotrophic lateral sclerosis. Cell 1993;73: 35-46
100. Lee MK, Marszalek JR, Cleveland DW. A mutant neurofilament subunit causes massive, selective motor neuron death: Implications for the pathogenesis of human motor neuron disease. Neuron 1994;13:975-988
101. Collard JF, Core F, Julien JP. Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis. Nature 1995;375:61-64
102. Williamson TL, Bruijn LI, Zhu Q, et al. Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase. Proc Natl Acad Sci USA 1998;95(16):9631-9636
103. Julien JP, Couillard-Despres S, Meier J. Transgenic mice in the study of ALS: The role of neurofilaments. Brain Pathol 1998; 8(4):759-769
104. Couillard-Depres S, Zhu Q, Wong PC, Price DL, Cleveland DW, Julien JP. Protective effect of neurofilament heavy gene over-expression in motor neuron disease induced by mutant superoxide dismutase. Proc Natl Acad Sci USA 1998;95(16): 9626-9630
105. Mizusawa H, Matsumoto S, Yen SH, Hirano A, Rojas-Corona RR, Donnenfeld H. Focal accumulation of phosphorylated neurofilaments within anterior horn cell in familial amyotrophic lateral sclerosis. Acta Neuropathol (Berl) 1989;79(1): 31-43
106. Dal Canto MC, Gurney ME. Neuropathological changes in two lines of mice carrying a transgene for mutant human CuZn-SOD and in mice overexpressing wild type human SOD: A model of familial amyotrophic lateral sclerosis (FALS). Brain Res 1995;676(1):25-40
107. Bruijn LI, Houseweart MK, Kato S, et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild type SOD1. Science 1998;281:1851-1853
108. Durham HD, Roy J, Dong L, Figlewicz DA. Aggregation of mutant CuZn superoxide dismutase proteins in a culture model of ALS. J Neuropathol Exp Neurol 1997;56(5):523-530
109. Ghadge GD, Lee JP, Bindokas VP, et al. Mutant superoxide dismutase-1-linked familal amyotrophic lateral sclerosis: Molecular mechanisms of neuronal death and protection. J Neurosci 1997;17(22):8756-8766
110. Hottinger AF, Fine EG, Gurney ME, Zurn AD, Aebischer P. The copper chelator d-penicilamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis. Eur J Neurosci 1997;9(7):1548-1551
111. Kostic V, Jackson-Lewis V, deBibao F, Dubois-Dauphin M, Przedborski S. Bcl-2: Prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 1997; 277(5325):559-562
112. Nagano S, Ogawa Y, Yanagihara T, Sakoda S. Benefit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model in mice. Neurosci Lett 1999; 265:159-162
113. Klivenyi PK, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Med 1999;5(3):347-350
114. Trieu VN, Uckun FM. Genistein is neuroprotective in murine models of familial amyotrophic lateral sclerosis. Biochem Biophys Res Commun 1999;258:685-688
115. Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 1998;55(4):526-528
116. Vyth A, Timmer JG, Bossuyt PM, Louwerse ES, deJong JM. Survival in patients with amyotrophic lateral sclerosi, treated with an array of antioxidants. J Neurol Sci 1996;139(suppl.): 99-103
117. Mazzini L, Mora G, Balzarini C, et al. The natural history and the effects of gabapentin in amyotrophic lateral sclerosis. J Neurol Sci 1998;160(suppl. 1):S57-63
118. Delmsen KC, Lynch T, Pavlou E, et al. Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. Am J Hum Genet 1994;55:1159-1165
119. Wilhelmsen KC, Clark LN, Miller BL, Geschwind DH. Tau mutations in frontotemporal dementia. Dement Geriatr Cogn Disord 1999;10(suppl. 1):88-92
120. Gajdusek DC. Foci of motor neuron disease in high incidence in isolated populations of East Asia and the Western Pacific. Adv Neurol 1982;36:363-393
121. Brody JA, Hirano A, Scott RM. Recent neuropathologic observations in amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. Neurology 1971;21:28-36
122. Perez-Tur J, Buee L, Morris HR, et al. Neurodegenerative diseases of Guam: Analysis of TAU. Neurology 1999;53(2): 411-113
123. Duncan MW, Steele JC, Kopin IJ, Markey SP. 2-Amino-3-(methylamino)-propanoic acid (BMAA) in cyad flour: An unlikely cause of amyotrophic lateral sclerosis and Parkinsonism-dementia of Guam. Neurology 1990;40:767-772